Hengrui Pharma Secures NMPA Approval for First-in-Class Rivocibart Injection Targeting Rare HoFH

Bulletin Express11-12

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, HKEX:01276) has received marketing authorisation from China’s National Medical Products Administration (NMPA) for Rivocibart Injection, a self-developed Class 1 therapeutic biological product for the treatment of homozygous familial hypercholesterolaemia (HoFH) in patients aged 12 years and above.

Rivocibart, administered as a 300 mg/2 mL subcutaneous, pre-filled auto-injector, is an angiopoietin-like protein 3 (ANGPTL3) monoclonal antibody designed to lower triglycerides and low-density lipoprotein cholesterol (LDL-C) in HoFH patients who suffer from severely impaired LDL receptor function. Current mainstream lipid-lowering therapies are often inadequate for this population, underscoring the medical need addressed by Rivocibart.

The approval is supported by the randomized, double-blind, placebo-controlled Phase III study SHR-1918-301, which evaluated efficacy and safety in HoFH patients aged ≥12 and was highlighted in a Late-Breaking Science session at the European Society of Cardiology Congress 2026.

Hengrui Pharma has invested approximately RMB 302.90 million in the Rivocibart development programme to date (unaudited). The company will enter a market currently served internationally by Regeneron’s EVKEEZA (evinacumab-dgnb), which recorded global sales of USD 216 million in 2025, according to EvaluatePharma.

Management emphasised continued vigilance over production and commercial execution, noting that market uptake remains subject to regulatory and operational uncertainties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment